Skip to main content
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. — Investor Relations & Filings

Ticker · SLS ISIN · US81642T2096 LEI · 549300VZIH50VYURLQ98 US Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2012-04-30 Proxy Solicitation & In…
Country US United States of America
Listing US SLS

About SELLAS Life Sciences Group, Inc.

https://www.sellaslifesciences.com/

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's core activity involves advancing its pipeline of cancer immunotherapies, which are designed to utilize the patient's immune system to combat various malignancies. Its development programs aim to address significant unmet medical needs in oncology by creating new treatment options for cancer patients.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2012-04-30 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering, specifically concerning shares of common stock issuable upon exercise of warrants. It includes detailed information about the offering, risk factors, use of proceeds, plan of distribution, and legal matters. The document is part of a registration statement filed with the SEC under the Securities Act of 1933. This type of document is a capital markets filing related to fundraising and securities issuance, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Hence, the classification is CAP with high confidence.
2012-04-20 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an amendment to a securities purchase agreement, extension of termination dates, and conditional dividend information related to a financing transaction. There are no financial statements or detailed financial performance data included, nor is this a full annual or quarterly report. The document focuses on a capital transaction update and related corporate actions. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and contains substantive information about financing activities, not just an announcement of a report, so it is not an RPA or RNS filing.
2012-04-19 English
PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Preliminary Proxy Statement filed on Schedule 14A with the SEC, as indicated by the header and the text. It includes detailed information about the upcoming Annual Meeting of Stockholders, including proposals to be voted on, voting procedures, and other meeting-related information. The document is not an announcement of voting results, nor is it a report of financial results or management discussion. It is clearly a proxy solicitation document intended to inform shareholders and solicit their votes for the Annual Meeting. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is the proxy statement itself, not just an announcement or notice.
2012-04-18 English
PRIMARY DOCUMENT
Director's Dealing
2012-04-17 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes announcements about the closing of a public offering, establishment of a new record date for a conditional dividend, and entry into a material definitive agreement. There are no detailed financial statements or comprehensive financial analysis present, only event disclosures. The document also references a press release as an exhibit. This type of filing is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement reporting significant corporate events but not a full financial report or other specific report type.
2012-04-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.